Product Description
HRX-215 is a small molecule inhibitor of Mitogen-Activated Protein (MAP) Kinase Kinase 4 (MKK4). (Sourced from: https://www.heparegenix.com/heparegenix-publishes-data-for-its-first-in-class-mkk4-inhibitor-hrx-215-for-the-treatment-of-acute-and-chronic-liver-diseases-in-cell/)
Mechanisms of Action: MKK4 Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|